Web Exclusives

Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer. Read Article ›

Information on clinical aspects of COVID-19 and social and financial support services for the cancer community are abundant. Read Article ›

In a systematic literature review that extracted data from 50 qualifying clinical trials, PARP inhibitor first-line maintenance improved progression-free survival (PFS) “across the board” versus other maintenance treatments in women with advanced ovarian cancer. Read Article ›

In a single-arm, single-institution study, combining pembrolizumab, bevacizumab, and metronomic oral cyclophosphamide led to a median progression-free survival of 10 months in women with recurrent ovarian cancer, with better response in women with platinum-sensitive disease. Read Article ›

An online educational tool about PARP inhibitors improved clinicians’ confidence in their ability to use them correctly in women with newly diagnosed advanced ovarian cancer. Read Article ›

Establishing protocols for side-effect reporting and management beforehand can maximize adherence to PARP inhibitor maintenance therapy. Read Article ›

Although the combination of bevacizumab and olaparib showed superior progression-free survival compared with bevacizumab plus placebo as upfront maintenance therapy in women with advanced ovarian cancer, the lack of an olaparib monotherapy comparator limits meaningful interpretation. Read Article ›

The rate of overall survival was similar between nivolumab and either gemcitabine or pegylated liposomal doxorubicin in the open-label, randomized phase 3 NINJA clinical trial of patients with platinum-resistant ovarian cancer, but the overall duration of response was longer in the nivolumab arm. Read Article ›

In the FORWARD II clinical trial, mirvetuximab soravtansine combined with carboplatin and bevacizumab induced an overall response rate of 83% in patients with recurrent platinum-sensitive ovarian cancer. Read Article ›

Copay maximizer programs are replacing copay accumulator programs, and the trend toward increasing cost burden for patients continues. Read Article ›

The combination of dabrafenib and trametinib performs as well in the real world as in clinical trials in patients with BRAF V600-mutated advanced melanoma and brain metastases, but the medical need for patients with brain metastases remains high. Read Article ›

The combination of ipilimumab and anti–PD-1 therapy showed efficacy comparable to clinical trial populations in patients with preexisting autoimmune disease and advanced melanoma. Read Article ›

Page 1 of 14

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: